Naproxen vs. Meloxicam for Migraine Pain

Naproxen and meloxicam both turn up in headache treatment, and both are NSAIDs, but they are working in different ways and earning their place in different parts of a migraine plan. Naproxen is the workhorse for acute migraine attacks. Meloxicam is more of a preventive-leaning, once-daily NSAID that occasionally gets pulled into migraine treatment when a steadier baseline is needed. Mixing them up — or assuming one can simply replace the other — usually leads to a less effective plan.

This piece walks through how they differ, where each one earns its place, and what the trade-offs look like.

The basic distinction

Naproxen is a long-acting non-selective NSAID used for acute migraine treatment, often as a single 500–825 mg dose at the first sign of an attack. It is available over the counter, well-studied in migraine, and the first-line NSAID in most acute-treatment plans.

Meloxicam is a preferentially COX-2-selective NSAID dosed once daily at 7.5 mg or 15 mg, typically used for arthritis and chronic musculoskeletal pain. In migraine it is sometimes used off-label as a short-course preventive — for example, around menstrual windows or during high-trigger seasons — rather than as an attack-aborter.

How they differ

Property	Naproxen	Meloxicam
Drug class	Non-selective NSAID	Preferential COX-2 NSAID
Half-life	12–17 hours	15–20 hours
Typical dose	500–825 mg at onset	7.5–15 mg once daily
Onset of effect	30–60 minutes	Slow — steady state over days
Migraine use	Acute aborter	Short-course preventive (off-label)
OTC availability	Yes (naproxen sodium 220 mg)	Prescription only
GI side-effect risk	Moderate	Lower at standard doses
Cardiovascular risk	Lower than COX-2-selective	Slightly higher (COX-2 lean)

The big practical difference is onset. Naproxen kicks in within an hour and is built around the acute attack. Meloxicam works by holding a steady NSAID level day-to-day; it is not the drug to reach for when a migraine is already starting.

When naproxen is the right choice

For acute migraine, naproxen is almost always the better choice between the two. Specifically:

• Acute migraine attacks at onset, alone or with a triptan.
• Menstrual migraine as a short-course aborter around the high-risk window.
• Migraine recurrence prevention paired with a triptan that wears off too quickly.
• Mild-to-moderate migraine where a single NSAID is enough to abort the attack.

Meloxicam is poorly suited to any of these — its slow onset means a migraine that has already started will not be controlled by a single meloxicam dose.

When meloxicam earns its place

Meloxicam has a narrower role in migraine, but a real one:

1. Short-course menstrual prophylaxis. A few days of meloxicam in the days leading up to and through the menstrual window can dampen menstrual migraine frequency in some patients, in the same way long-acting NSAIDs have been used for years for mini-prophylaxis.

2. Concurrent arthritis or musculoskeletal pain. Patients on meloxicam already — for example, for osteoarthritis or rheumatoid arthritis — sometimes find that their migraine frequency is dampened as a side effect of the steady NSAID load. In this case, doubling up on naproxen would not be appropriate, and the meloxicam acts as both arthritis treatment and migraine background.

3. Brief preventive trials. A short trial of daily meloxicam during a known high-trigger period — say, a high-pollen window or a stretch of unstable weather — is occasionally used when patients do not tolerate triptans or first-line preventives.

For an acute attack that has already started, neither of these scenarios applies. Use naproxen.

Side-effect comparison

Both drugs share the standard NSAID side-effect concerns, but the profiles differ in ways that matter for long-term use.

• GI effects. At standard doses, meloxicam has a somewhat lower rate of GI bleeding and ulceration than naproxen, owing to its COX-2 lean. The advantage shrinks at the 15 mg dose.
• Cardiovascular risk. COX-2-selective and -preferential drugs carry a higher cardiovascular event rate than non-selective NSAIDs. Naproxen has one of the more favorable cardiovascular profiles of the NSAID class. For patients with cardiovascular risk factors, naproxen is generally preferred.
• Renal effects. Comparable per dose — both carry the standard NSAID kidney risks and should be used cautiously in patients with chronic kidney disease.
• Blood pressure. Both can raise blood pressure modestly with sustained use.

Drug interactions

The interaction profiles overlap heavily: additive bleeding risk with anticoagulants, reduced antihypertensive effect of ACE inhibitors and ARBs, raised lithium levels, additive GI bleeding risk with SSRIs. Both should be used cautiously alongside other NSAIDs to avoid stacking the side-effect load.

Practical decision tree

The simplified version of how to think about it:

1. Is this an acute migraine starting right now? Use naproxen, or sumatriptan plus naproxen. Meloxicam is not an attack drug.
2. Is there a known high-trigger window coming up (menstrual cycle, season)? A short course of meloxicam can be considered as background NSAID prophylaxis.
3. Is the patient already on meloxicam for arthritis? Continue it; layer triptans or short-course naproxen for acute attacks only with clinician guidance.
4. Has naproxen failed and another NSAID is being considered? Meloxicam is rarely the next step for acute migraine; a different acute approach (triptan, gepant) is usually better.

Where pressure tracking fits

For weather-triggered migraine specifically, the timing question is everything. Naproxen taken at the first symptom of a barometric pressure shift can blunt the attack before it escalates. Pressure Pal works as a migraine tracker app that flags pressure changes ahead of time, which gives you a window to take naproxen early — and logging which attacks respond well versus poorly helps you and your clinician decide whether a steadier background plan, possibly including a short course of meloxicam during high-trigger windows, would help.